0000000001205227

AUTHOR

Christine Silvain

showing 3 related works from this author

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

2021

Summary Background Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection. Aims We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure. Methods Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated. Results No bleeding complication was reported. One and two liver failures were respect…

medicine.medical_specialtyCarcinoma HepatocellularNeutropeniaurologic and male genital diseasesPlaceboPlacebo groupGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansChemoembolization TherapeuticHepatologybusiness.industrySunitinibLiver NeoplasmsGastroenterologyLiver failuremedicine.diseaseAcute toxicityTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDose reductionbusinessLiver Failuremedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

2021

International audience; Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver …

Blood PlateletsLiver CirrhosisNoninvasive Diagnosismedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]PopulationEsophageal and Gastric VaricesChronic liver diseaseSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseEsophageal varicesInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationBaveno VI CriteriaRetrospective Studieseducation.field_of_studyHepatologybusiness.industryGastroenterologyRetrospective cohort studyPortal Hypertensionmedicine.disease3. Good healthMELDCirrhosis030220 oncology & carcinogenesisElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessBaveno VI Criteria Blood Platelets Cirrhosis Elasticity Imaging Techniques End Stage Liver Disease Esophageal and Gastric Varices Humans Liver Cirrhosis MELD Noninvasive Diagnosis Portal Hypertension Retrospective Studies Severity of Illness Index
researchProduct

Is ribavirin actually useful for Genotype 1 cirrhotic patients who receive DAAs combination? An updated meta-analysis of randomized controlled trials

2015

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
researchProduct